ABOUT IRDES

PUBLICATIONS

INTERNATIONAL

SURVEYS

CONFERENCES & WORKSHOPS

OUR SERVICES...

CATHERINE SERMET

Deputy Director

Doctor in Medicine


33 (0)1 53 93 43 37 sermet@irdes.fr Assistant: Catherine Banchereau

RESEARCH ACTIVITIES

Research interest

  • Prescription drugs, medical goods
  • Health status, risk factors
  • Inequalities in health and health care use

Current interest

  • Impact of drug delisting
  • Price determinants of me-too drugs
  • Diffusion of pharmaceutical innovation
  • Drug prescription efficiency
  • Health care use of individuals with disabilities

Other activities

LATEST ENGLISH PUBLICATIONS


Measuring Polypharmacy in the Elderly: Impact of the Method on Prevalence and Therapeutic Classes
Le Cossec C. (Irdes), Sermet C. (Irdes), in collaboration with Perronnin M. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n░ 213. 2015/10.

Generic Pregabalin; Current Situation and Implications for Health Authorities, Generics and Biosimilars Manufacturers in the Future.
Godman B., Wilcock M., Martin A., Bryson S., Baumgärtel C., Bochenek T., de Bruyn W., Sović Brkičić L., D’Agata M., Fogele A., Coma Fusté A., Fraeyman J., Fürst J., Garuoliene K., Herholz H., Hoffmann M., Jayathissa S., Kwon H.-Y., Langner I., Kalaba M., Andersén Karlsson E., Laius O., Markovic-Pekovic V., Magnusson E., McTaggart S., Metcalfe S., Bak Pedersen H., Piessnegger J., Ringerud A.-M., .W Selke G., Sermet C., Schiffers K., Skiold P., Slabý J., Tomek D., Viksna A., Vitry A., Zara C., Malmström R.-E., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 4, n°3, 2015/09, 125-135.
On gabi-journal site

People with Disabilities Living at Home have Lower Access to Preventive Care than People without Disabilities Exploitation of the Health and Disability Survey, Household Section (2008)
Penneau A., Pichetti S., Sermet C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n░ 208. 2015/04.

Institutionalisation Favours Access to Health Care for Disabled Persons Aged under 60 in France
Exploitation of the Health and Disability Households and Institutions survey (2008-2009)

Penneau A., Pichetti S., Sermet C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n░ 207. 2015/03.

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.
Parkinson B., Sermet C., Clement F., Crausaz S., Godman B., Garner S., Choudhury M., Pearson S.A., Viney R., Lopert R., Elshaug A.G. Pharmacoeconomics. 1-20 vol 33, Issue 9, 2015/09, 905-924.
On springer link site

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B., Malmström R.E., Diogene E., Gray A., Jayathissa S., Timoney A., Acurcio F., Alkan A., Brzezinska A., Bucsics A., Campbell S.M., Czeczot J., de Bruyn W., Eriksson I., Yusof F.A., Finlayson A.E., Fürst J., Garuoliene K., Guerra Júnior A., Gulbinovič J., Jan S., Joppi R., Kalaba M., Magnisson E., McCullagh L., Miikkulainen K., Ofierska-Sujkowska G., Pedersen H.B., Selke G., Sermet C., Spillane S., Supian A., Truter I., Vlahović-Palčevski V., Vien L.E., Vural E.H., Wale J., Władysiuk M., Zeng W., Gustafsson L.L. Expert Review of Clinical Pharmacology, vol 8, n°1, 2015/01, 77-94.

Polypharmacy: definitions, measurement and stakes involved Review of the literature and measurement tests
Monégat M. (Irdes), Sermet C. (Irdes) In collaboration with Perronnin M. (Irdes) and Rococo E. (Institut Gustave Roussy-IGR)
Issues in Health Economics (Questions d'économie de la santé) n░ 204. 2014/12.

Entry time effects and follow-on drug competition.
Andrade L.F., Sermet C., Pichetti S., European Journal of Health Economics, on line le 12/12/2014. vol 17 n°1, 2016/01, 45-60.
On springer links site

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Godman B., Malmström R.E., Diogene E., Jayathissa S., McTaggart S., Cars T., Alvarez-Madrazo S., Baumgärtel C., Brzezinska A., Bucsics A., Campbell S., Eriksson I., Finlayson A., Fürst J., Garuoliene K., Gutiérrez-Ibarluzea I., Hviding K., Herholz H., Joppi R., Kalaba M., Laius O., Malinowska K., Pedersen H.B., Markovic-Pekovic V., Piessnegger J., Selke G., Sermet C., Spillane S., Tomek D., Vončina L., Vlahović-Palčevski V., Wale J., Wladysiuk M., van Woerkom M., Zara C., Gustafsson L.L. Frontiers in Pharmacology. vol 5, article 109, 2014/06, 1-11.
On ncbi site

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Godman B., Wettermark B., van Woerkom M., Fraeyman J., Alvarez-Madrazo S., Berg C., Bishop I., Bucsics A., Campbell S., Finlayson A.E., Fürst J., Garuoliene K., Herholz H., Kalaba M., Laius O., Piessnegger J., Sermet C., Schwabe U., Vlahović-Palčevski V.V., Markovic-Pekovic V., Vončina L., Malinowska K., Zara C., Gustafsson L.L. Frontiers in Pharmacology, vol 5, article 106, 2014/06, 1-9.
On ncbi site

The 2012 Health, Health Care and Insurance Survey (ESPS)
First Results

Célant N., Dourgnon P., Guillaume S., Pierre A., Rochereau T., Sermet C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 198. 2014/05.

Disabled Persons’ Access to Dental, Ophthalmological and Gynaecological Care in France
Exploitation of the Health and Disability Households survey (Enquête Handicap-Santé Ménages)

Lengagne P., Penneau A., Pichetti S., Sermet C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 197. 2014/04

Factors Influencing Report of Common Mental Health Problems Among Psychologically Distressed Adults.
Khlat M., Legleye S., Sermet C., Community Mental Health Journal, on line 20/12/2013, 1-7
On SpringerLink site

The Diffusion of New Anti-diabetic drugs: an International Comparison
Pichetti S. (Irdes), Sermet C. (Irdes), Van der Erf S. (Cnamts)
Issues in Health Economics (Questions d'économie de la santé) n° 187. 2013/05.

Personalizing health care: feasibility and future implications.
Godman B., E. Finlayson A., K. Cheema P., Zebedin-Brandl E., Gutiérrez-Ibarluzea I., Jones J., E. Malmström R., Asola E., Baumgärtel C., Bennie M., Bishop I., Bucsics A., Campbell S., Diogene E., Ferrario A., Fürst J., Garuoliene K., Gomes M., Harris K., Haycox A., Herholz H., Hviding K., Jan S., Kalaba M., Kvalheim C., Laius O., Lööv S.A., Malinowska K., Martin A., McCullagh L., Nilsson F., Paterson K., Schwabe U., Selke G., Sermet C. et al. BMC Medicine, vol 11, 2013/08, 1-23.
On BMC Medicine site

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström R.E., Godman B.B., Diogene E., Baumgärtel C., Bennie M., Bishop I., Brzezinska A., Bucsics A., Campbell S., Ferrario A., Finlayson A.E., Fürst J., Garuoliene K., Gomes M., Gutiérrez-Ibarluzea I., Haycox A., Hviding K., Herholz H., Hoffmann M., Jan S., Jones J., Joppi R., Kalaba M., Kvalheim C., Laius O., Langner I., Lonsdale J., Lööv S.Å., Malinowska K., McCullagh L., Paterson K., Markovic-Pekovic V., Martin A., Piessnegger J., Selke G., Sermet C., Simoens S., Tulunay C., Tomek D., Vončina L., Vlahovic-Palcevski V., Wale J., Wilcock M., Wladysiuk M., van Woerkom M., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 4, article 39, 2013/05, 1-31.
On Frontiers site

Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France.
Pichetti S., Sermet C., Godman B., Campbell S.M., Gustafsson L.L., Applied Health Economics and Health Policy, on line, 2013/04, 1-14.
On Springer Link site

Essential to increase the use of generics in Europe to maintain comprehensive health care ?
Godman B., Bennie M., Baumgärtel C., Sovic-Brkicic L., Burkhardt T., Fürst J., Garuoliene K., Gomes M., Markovic-Pekovic V., Martin A., Sermet C., Skiold P., Van Woerkom M., Voncina L., Gustafsson L.L., Farmeconomia. Health economics and therapeutic pathways, 2012, vol 13, Suppl n°3S, 5-20.
On Farmeconomia site

How to Explain Price Gaps between Me-too Drugs?
A 2001-2009 Panel-data Analysis

Bergua L. (CHU de Rouen), Cartier T. (Université Paris Diderot, Sorbonne Paris Cité, Irdes), Célant N. (Irdes), Pichetti S. (Irdes), Sermet C. (Irdes), Sorasith C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 178. 2012/07-08.

European payer initiatives to reduce prescribing costs through use of generics.
Godman B., Wettermark B., Sermet C. et al., GaBi Journal : Generics and Biosimilars Initiative Journal, vol. 1, issue 1, 2012, 22-27.
On GaBi Journal site

What lessons can be learned from the launch of generic clopidogrel?
Baumgärtel C., Godman B., Malmstrom R.E., Andersen M., Abuelkhair M., Abdu S., Bennie M., Bishop I., Burkhardt T., Fahmy S., Furst J., Garuoliene K., Herholz H., Kalaba M., Koskinen H., Laius O., Lonsdale J., Malinowska K., Ringerud A.M., Schwabe U., Sermet C., Skiold P., Teixeira I., van Woerkom M., Vitry A., Vončina L., Zara C., Gustafsson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 58-68.
On GaBi Journal site

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach.
Godman B., Abuelkhair M., Vitry A., Abdu S., Bennie M., Bishop I., Fahmy S., Garuoliene K., Herholz H., Martin A., Malmstrom R.E., Jan S., Schwabe U., Sermet C., Skiold P., Voncina L., Gustaffson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 69-83.
On GaBi Journal site

Analysis of the Impact of Drug Delisting in France between 2002 and 2011
Pichetti S., Sermet C.
Issues in Health Economics (Questions d'économie de la santé) n° 167. 2011/07-08

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on presciption rates: A time-series analysis for France 1998-2010.
Pichetti S., Sorasith C., Sermet C., Health Policy, vol.102, issues 2-3, 2011/10, 159-169.

The Health of Older Workers in Europe: Results of SHARE 2006
Lenormand M.-C., Sermet C., Sirven N.
Issues in Health Economics (Questions d'économie de la santé) n° 160. 2010/12

Policies to enhance prescribing efficiency in Europe: findings and future implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., Lonsdale J., Malmström R.E., Martikainen J.E., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahovic-Palcevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 1, article 141, 2011/01, 1-16.
On Frontiers site

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization : changes seen and global implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., McGinn D., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahović-Palčevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Expert Review of Pharmacoeconomics & Outcomes Research, vol 10, n°6, 2010/12, 707-722.
On Expert reviews site

Use of Generics - A Critical Cost Containment Measure for All Healthcare Professionals in Europe ?
Godman B., Shrank W., Wettermark B., Andersen M., Bishop I., Burkhardt T., Garuolienè K., Kalaba M., Laius O., Joppi R., Sermet C., Schwabe U., Teixeira I., Cankat Tulunay F., Wendykowska K., Zara C., L. Gustafsson L., Pharmaceuticals, vol 3, n°2, 2010, 2470-2494.
On MDPI site

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholzl H., Wendykowska K., Laius O., Jan S., Sermet C., Zara C., Kalaba M., Gustafsson R., Garuoliene K., Haycox A., Garattini S., Gustafsson L.L., BMC Health Services Research, vol 10, n°153, 1-29, 2010/06.
On Biomedcentral site

Ongoing pharmaceutical reforms in France : Implications for Key Stakeholder Groups, Sermet C., Andrieu V., Godman B., Van Ganse E., Haycox A ., Reynier J.P., Applied Health Economics and Health Policy, vol 8, n°1, 2010, 7-24
Abstract

Immigrants’ Access to Ambulatory Care in France
Dourgnon P., Jusot F., Sermet C., Silva J., 2009/09.
Questions d'Úconomie de la santÚ n° 146

Self-assessed health of individuals aged 55 and over in France and Québec: differences and similarities
Camirand J. (ISQ), Sermet C. (Irdes) , Dumitru V. (ISQ), Guillaume S. (Irdes), 2009/05
Questions d'économie de la santé n° 142

Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom
Grandfils N., Sermet C.
Working paper n° 21, 2009/02

New obesity body mass index threshold for self-reported data. Dauphinot V., Wolff H., Naudin F., Gueguen R., Sermet C., Gaspoz J.M., Kossovsky M.P., Journal of Epidemiology and Community Health, 2009/02, vol 63, n°2, 128-132.
Abstract

Self assessed health of immigrants in France - Analysis of the 2002-03 decennial health survey
Dourgnon P., Jusot F., Sermet C., Silva J., 2008/07 (March 2009 for the English version)
Questions d'Úconomie de la santÚ n° 133

Social heterogeneity in self-reported health status and measurement of inequalities in health
Tubeuf S., Jusot F., Devaux M., Sermet C.
Working paper n° 12, 2008/06

Delisting of mucolytics and expectorants: what is the impact on general practitioners’ prescribing?
Devaux M., Grandfils N., Sermet C., 2007/12
Questions d'Úconomie de la santÚ n° 128

Job loss from poor health, smoking and obesity : a national prospective survey in France. Jusot F., Khlat M., Rochereau T., Sermet C., Journal of Epidemiology and Community Health, n°4, vol 62, 2008/04, 332-337.
Full text on the JECH's site

Bad health strongly increases the risk of becoming unemployed or inactive
Jusot F., Khlat M., Rochereau T., Sermet C. September 2007
Questions d'Úconomie de la santÚ n° 125

What do we suffer from? Evaluation of declared diseases in France Decennial Health Survey, Insee 2002-2003.Allonier C., Guillaume S., Sermet C., 2007/06
Questions d'Úconomie de la santÚ n° 123

Health working life expectancies at age 50 in Europe : a new indicator, Lièvre A., Jusot F., Barnay T., Sermet C., Brouard N., Robine J.M., Brieu M.A., Forette F., The Journal of Nutrition, Health & Aging, vol 11, n° 6, 2007
Full text on the JNHA site

Differences between reported and diagnosed morbidity The examples of obesity, arterial hypertension and hypercholesterolemia. Dauphinot V., Naudin F., Gueguen R.(CETAF), Perronnin M., Sermet C. (Irdes), 2006/11
Questions d'Úconomie de la santÚ n° 114

Pharmaceutical policy in France : a mosaic of reforms.Grandfils N., Sermet C., Eurohealth, 2006, vol.12, n° 3, 15-17.
Full text on the LSE site

Expenditure on prevention and care by disease in France
Fénina A., Geffroy Y., Minc C., Renaud T., Sarlon E, Sermet C., 2009/07
Questions d'Úconomie de la santÚ n° 111

The politics of drug reimbursement in England, France and Germany.
N'Guyen L., Or Z. , Paris V. , Sermet C. 2005/10
Questions d'Úconomie de la santÚ n° 99

Are measures of health and economic activity comparable in european surveys?
Barnay T., Jusot F., Rochereau T., Sermet C. 2005/06
Questions d'Úconomie de la santÚ n° 96

Comparability of health surveys in Europe : France, United Kingdom, Russia, Poland, Czech Republic, Germany, Greece, Italy, Spain and Sweden."Indicators of active life expectancy" - Project International Longevity Centre, Barnay T., Jusot F., Rochereau T., Sermet C., Irdes/ILC, 2005/02/28.
Report
Appendix

Drug delisting and reduced reimbursement
Naudin F., Sermet C., Health Policy Monitor, 2003
Full text on the International network health policy & reform's site

More information on the French Site

Our newsletter
Subscribe
Contact
Legal information
Sitemap
Useful links
Access
News
Latest publications
RSS


September 25th, 2015